High tumor burden in patients with non-small-cell lung cancer: a Delphi survey among Spanish oncologists

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71, 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines diagnosis, treatment and follow-up. Ann. Oncol.29, 192–237 (2018).
   Web of Science ®Google Scholar
• Meza R , MeernikC, JeonJet al. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLOS ONE10, e0121323 (2020).
   Google Scholar
• American Cancer Society . Lung cancer survival rates (2022). www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survivalrates.html
   Google Scholar
• Majem M , JuanO, InsaA. SEOM clinical guidelines for the treatment of non-small cell lung cancer. Clin. Transl. Oncol.21, 3–17 (2018).
   PubMed Web of Science ®Google Scholar
• Reck M , RabeKF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N. Engl. J. Med.377, 849–861 (2017).
   PubMed Web of Science ®Google Scholar
• Duma N , Santana-DavilaR, MolinaJR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc.94, 1623–1640 (2019).
   PubMed Web of Science ®Google Scholar
• Simarro J , Pérez-SimóG, MancheñoNet al. Impact of molecular testing using next-generation sequencing in the clinical management of patients with non-small cell lung cancer in a public healthcare hospital. Cancers (Basel)15(6), 1705 (2023).
   PubMed Web of Science ®Google Scholar
• Hsieh YT , ChiangBJ, WuCCet al. High tumor burden predicts poor response to enzalutamide in metastatic castration-resistant prostate cancer patients. Cancers (Basel)13, 3966 (2021).
   PubMed Web of Science ®Google Scholar
• Yonekawa Y , UeharaK, MizunoTet al. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score. Int. J. Clin. Oncol.26, 126–134 (2021).
   PubMed Web of Science ®Google Scholar
• Kudo M . A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE. Liver Cancer8, 299–311 (2021).
   Web of Science ®Google Scholar
• Hall M , SavvatisK, NixonKet al. Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome. Ann. Surg. Oncol.26, 2943–2951 (2021).
   Web of Science ®Google Scholar
• Zhu L , FengH, JinSet al. High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer. Tumour Biol.39, 101 (2017).
   Google Scholar
• Freeman CL , SehnLH. Initial treatment of high tumor burden follicular lymphoma. Hematol. Oncol. Clin. North Am.34, 673–687 (2020).
   PubMed Web of Science ®Google Scholar
• Fu Y , WangH, ZhaiXet al. Improved outcome of newly diagnosed childhood mature B-cell lymphoma/leukemia with high tumor burden treated with BFM95-based protocol combining rituximab: a report from Shanghai, China. J. Pediatr. Hematol. Oncol.41, 170–174 (2019).
   PubMed Web of Science ®Google Scholar
• Cottereau AS , VersariA, LuminariSet al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Blood131, 2449–2453 (2018).
   PubMed Web of Science ®Google Scholar
• Gomez OH , PaulAM, GranadosALet al. “High tumor burden” in metastatic non-small cell lung cancer: defining the concept. Cancer Manag. Res.13, 4665–4670 (2021).
   PubMed Web of Science ®Google Scholar
• Shang Z . Use of Delphi in health sciences research: a narrative review. Medicine (Baltimore)102(7), e32829 (2023).
   PubMed Web of Science ®Google Scholar
• Likert Rensis . A technique for the measurement of attitudes. Arch. Psychol.140, 1–55 (1932).
   Google Scholar
• Sakata Y , KawamuraK, IchikadoKet al. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac. Cancer10, 2259–2266 (2019).
   PubMed Web of Science ®Google Scholar
• Gerber DE , DahlbergSE, SandlerABet al. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br. J. Cancer109(6), 1476–1481 (2013).
   PubMed Web of Science ®Google Scholar
• Xu Z , YangQ, ChenXet al. Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: a population-based study. Oncol. Lett.17, 5590–5600 (2019).
   PubMed Web of Science ®Google Scholar
• Milovanovic IS , StjepanovicM, MitrovicD. Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: an autopsy study. Ann. Thorac. Med.12, 191–198 (2017).
   PubMed Web of Science ®Google Scholar
• Gibson AJW , LiH, D’SilvaAet al. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Med. Oncol.35, 117 (2018).
   PubMed Web of Science ®Google Scholar
• Shintani T , MatsuoY, IizukaYet al. Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy. Anticancer Res.37, 5161–5167 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao SJ , WuN, ZhengRet al. Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi35, 754–757 (2013).
   PubMedGoogle Scholar
• Andraos TY , HalmosB, ChengHet al. Disease burden on PET predicts outcomes for advanced NSCLC patients treated with first-line immunotherapy. Clin. Lung Cancer23(4), 291–299 (2022)
   PubMed Web of Science ®Google Scholar
• Facchinetti F , MazzaschiG, BarbieriFet al. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur. J. Cancer130, 155–167 (2020).
   PubMed Web of Science ®Google Scholar
• Wang S , ZhaoJ, WangCet al. Prognosis and role of clinical and imaging features in patients with malignant pericardial effusion: a single-center study in China. BMC Cardiovasc. Disord.21, 565 (2021).
   PubMed Web of Science ®Google Scholar
• McKay MJ . Brain metastases: increasingly precision medicine-a narrative review. Ann. Transl. Med.9, 1629 (2021).
   PubMed Web of Science ®Google Scholar
• Ren Y , DaiC, ZhengHet al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget7, 53245–53253 (2016).
   PubMedGoogle Scholar
• Campillo-Recio D , JimenoAriztia M, FloxBenítez Get al. Metastatic spinal cord compression: incidence, epidemiology and prognostic factors. Rev. Clin. Esp. (Barc.)219(7), 386–389 (2019).
   PubMed Web of Science ®Google Scholar
• Shamji FM , BeauchampG, MaziakDEet al. Paraneoplastic syndromes in lung cancers: manifestations of ectopic endocrinological syndromes and neurologic syndromes. Thorac. Surg. Clin.31(4), 519–537 (2021).
   PubMed Web of Science ®Google Scholar
• Patriarcheas V , GrammoustianouM, PtohisNet al. Malignant superior vena cava syndrome: state of the art. Cureus14(1), e20924 (2022).
   PubMed Web of Science ®Google Scholar
• Jotte RM , BatusM, BernickerEet al. IMpower150: exploratory efficacy analysis in patients (pts) with bulky disease. J. Clin. Oncol.38, e21637 (2020).
   Google Scholar
• Garassino MC , GadgeelS, EstebanEet al. Abstract CT043: outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: results from the KEYNOTE-189 study. Cancer Res.79, CT043 (2019).
   Web of Science ®Google Scholar
• Gelsomino F , FacchinettiF, SisiMet al. PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination. Immunotherapy13(5), 363–369 (2021).
   PubMed Web of Science ®Google Scholar
• Wang L , YangY, YuJet al. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: a systematic review and network meta-analysis. Thorac. Cancer13(3), 322–337 (2022).
   PubMed Web of Science ®Google Scholar
• Lang D , RitzbergerL, RambousekVet al. First-line pembrolizumab mono- or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes. Cancers (Basel)13(23), 6096 (2021).
   PubMed Web of Science ®Google Scholar